Business context and reporting period
IN8bio, Inc. is a clinical-stage biotechnology company developing gamma-delta T-cell therapies for solid and hematologic cancers. This Form 10-K covers the fiscal year ended December 31, 2023; it is an annual report, not a standalone fourth-quarter report. The company has no approved products and has generated no product revenue.
Its lead programs are INB-400, an autologous gamma-delta T-cell therapy in a Phase 2 trial for newly diagnosed glioblastoma (GBM); INB-200, in a Phase 1 GBM trial; and INB-100, in a Phase 1 trial for high-risk blood cancers in patients undergoing stem-cell transplantation. INB-300 and INB-500 remain preclinical.
Financial results and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $16.8 million | $14.1 million |
| General and administrative expense | $13.5 million | $14.5 million |
| Total operating expenses | $30.3 million | $28.5 million |
| Operating loss | $30.3 million | $28.5 million |
| Other income | $0.3 million | None reported |
| Net loss | $30.0 million | $28.5 million |
| Basic and diluted loss per share | $1.00 | $1.36 |
Research and development expense rose 20%, principally due to higher personnel costs and clinical activity in INB-100 and INB-200; lower INB-400 trial and manufacturing costs partly offset the increase. General and administrative expense declined about 7%, mainly from lower insurance, professional-service and salary costs. The lower loss per share in 2023 reflects a higher weighted-average share count; the company remained loss-making. Margins are not meaningful because there was no revenue.
Net cash used in operating activities was $23.3 million, versus $24.1 million in 2022. Investing activities used $0.6 million, down from $3.7 million. Financing activities provided $27.0 million, primarily from $14.4 million net ATM proceeds and $13.5 million net proceeds from the December private placement. Cash was $21.3 million at year-end, with an additional $0.3 million of restricted cash. Current assets were $24.6 million and current liabilities $5.4 million.
Total liabilities were $8.8 million. The company reported no long-term debt, but had finance-lease liabilities of $1.2 million and operating-lease liabilities of $3.7 million. Fixed lease payments totaled $6.0 million, including $2.0 million due within 12 months. Accumulated deficit was $91.2 million.
Material changes versus the prior period
- Net loss increased by $1.5 million, while operating cash use decreased by $0.8 million.
- Common shares outstanding increased from 24.5 million at year-end 2022 to 43.3 million at year-end 2023, reflecting ATM sales and the private placement. The December placement included 11.25 million common shares, 0.57 million pre-funded warrants, and 11.82 million each of Series A and Series B warrants.
- The company received $13.5 million net from the private placement and may receive up to approximately $32.5 million in additional gross warrant proceeds, subject to exercise and contractual conditions. Those proceeds are not assured and warrant exercises could further dilute shareholders.
Outlook, management commentary, and key risks
Management estimates that year-end cash will fund planned operating expenses and capital requirements only into January 2025. The auditor’s report includes an explanatory paragraph raising substantial doubt about the company’s ability to continue as a going concern. Management plans to seek additional equity or debt financing, collaborations, licensing, or other arrangements, while preserving cash. Failure to secure funding could require further cost reductions, delays, reduced scope, or discontinuation of development programs.
- Management expected initial INB-400 Phase 2 data in 2025. INB-200 updates were planned through 2024, with longer-term follow-up in 2025. INB-100 expansion enrollment was expected to continue in 2024, with topline results expected in 2025. These timelines depend on funding and are not guarantees.
- With additional funding, the company planned to submit an IND in 2025 for allogeneic INB-400 arms. INB-400 received FDA Orphan Drug Designation in April 2023; this is not marketing approval and does not ensure an expedited review.
- INB-200 interim results are from a small early-stage trial. The filing reported no treatment-related dose-limiting toxicities in the reported cohorts, but patient outcomes varied and follow-up was ongoing. INB-100 results were also preliminary: the filing describes 10 treated patients and encouraging remission observations, while noting a suboptimal-dose patient who was not evaluable and a relapse/death reported in the trial account. Investors should consult the underlying trial disclosures for definitions, patient status, and data cut-off dates.
- Key risks include limited cash runway and financing uncertainty; early-stage clinical and regulatory uncertainty; dependence on third-party manufacturers, facilities, and suppliers; complex cell-therapy manufacturing; patient enrollment and safety risks; competition; and possible dilution. The company also cited dependence on licensed intellectual property and exposure to loss of cash held above insured bank limits.
- The company reported no material legal proceedings. Management concluded disclosure controls and internal control over financial reporting were effective at December 31, 2023; the auditor did not attest to internal control effectiveness.
Important facts for investors to verify
- Current cash, actual cash burn, and updated runway compared with the filing’s January 2025 estimate; confirm what financing or cost actions followed year-end.
- Whether Series A or Series B warrants were exercised, redeemed, or remain outstanding, and the resulting share count and dilution.
- Updated INB-200 and INB-100 clinical data, including enrollment, evaluability, follow-up duration, adverse events, and consistency of reported patient outcomes.
- INB-400 Phase 2 enrollment and data timing, plus the funding and regulatory status of the proposed allogeneic trial arms.
- Whether clinical progress and manufacturing capacity support the stated timelines, given reliance on external facilities and suppliers.